Reported 1 day ago
Viking Therapeutics (VKTX) and Summit Therapeutics (SMMT) have seen their stock prices surge over 300% this year due to promising developments in their respective treatments — Viking’s oral weight loss drug and Summit’s cancer therapy. Analysts forecast further increases of up to 120% for Summit and 112% for Viking, citing strong market potential; however, investors are cautioned that these projections are not guarantees, and they should consider market valuations before investing.
Source: YAHOO